Logo
x

Search

Subscribe Now

 Approval

UCB’s Bimzelx (Bimekizumab-bkzx) Secures the US FDA’s Approval for Treating Moderate to Severe Hidradenitis Suppurativa (HS)

UCB’s Bimzelx (Bimekizumab-bkzx) Secures the US FDA’s Approval for Treating Moderate to Severe Hidradenitis Suppurativa (HS)

  • November 21, 2024
Jaguar Health Reports the US FDA’s Renewal of Conditional Approval for Canalevia-CA1 to Treat Chemotherapy-Induced Diarrhea in Dogs

Jaguar Health Reports the US FDA’s Renewal of Conditional Approval for Canalevia-CA1 to Treat Chemotherapy-Induced Diarrhea in Dog...

  • November 7, 2024
Merck Reports EC’s Approval of Keytruda for Two New Indications in Gynecologic Cancers

Merck Reports EC’s Approval of Keytruda for Two New Indications in Gynecologic Cancers

  • October 24, 2024
Eli Lilly Reports the MHRA’s Approval of Kisunla (Donanemab) to Treat Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease

Eli Lilly Reports the MHRA’s Approval of Kisunla (Donanemab) to Treat Mild Cognitive Impairment and Mild Dementia Due to Alzheimer...

  • October 23, 2024
Alvotech and Teva Reports the US FDA’s Approval for the Additional Presentation of Selarsdi (Biosimilar, Stelara)

Alvotech and Teva Reports the US FDA’s Approval for the Additional Presentation of Selarsdi (Biosimilar, Stelara)

  • October 23, 2024
Astellas Reports the US FDA’s Approval of Vyloy (Zolbetuximab-clzb) to Treat Advanced G/GEJ Cancer

Astellas Reports the US FDA’s Approval of Vyloy (Zolbetuximab-clzb) to Treat Advanced G/GEJ Cancer

  • October 21, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.